Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Data presented at #ESCCongress and published in the European Heart Journal show "substantial individual variability in the LDL-c reduction" for patients on inclisiran, highlighting the need for new therapies that can reliably reduce LDL-c levels. https://t.co/7iGv7ESGl4pic.twitter.com/KI22W5JRs2
— NewAmsterdam Pharma Corporation (@NewAmsPharma) January 24, 2023